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BACKGROUND. Breast cancer mortality rates are higher among African-American
women compared with white American women, yet little is known regarding
ethnicity-related variation in patterns of primary surgical treatment, locoregional
recurrence rates, and response to induction chemotherapy.
METHODS. The available literature was reviewed to evaluate outcome from breast-
conservation therapy in African-American women and response rates to systemic
therapy.
RESULTS. Breast-conservation therapy appears to be underused among African-
American women, a pattern that is noted also among white women with breast
carcinoma. Higher rates of locoregional recurrence are seen among African-Amer-
ican women regardless of whether they receive breast-conserving treatment or
undergo mastectomy, and this appears to be a function of primary tumor biology.
Response rates to appropriately delivered systemic therapy are similar for African-
American patients and white patients.
CONCLUSIONS. Despite the apparent increased aggressiveness of disease seen in
African-American women with breast carcinoma, patterns of response to local and
systemic therapy are similar to the patterns seen in white women with breast
carcinoma. Cancer 2003;97(1 Suppl):246 –52. © 2003 American Cancer Society.
DOI 10.1002/cncr.11015
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There is an abundance of data documenting a worse long-termoutcome and substantially higher mortality rates for African-
American patients with breast carcinoma compared with white pa-
tients.1– 6 However, there are limited reported data regarding ethnic-
ity-related variations in locoregional treatment failures and in tumor
responsiveness to induction systemic therapy. Improved understand-
ing of these topics is warranted, because it is well known that each is
predictive of outcome for the individual patient. In addition, closer
scrutiny of these outcome patterns may reveal variations in care for
breast carcinoma delivered to African-American patients.
Breast Conservation Therapy and Locoregional Recurrence
Breast conservation therapy (BCT), consisting of a margin negative
lumpectomy (with or without a staging axillary procedure) and breast
irradiation, is now well established as an oncologically safe and fre-
quently preferred treatment for patients with early-stage breast car-
cinoma. Overall survival is equivalent for appropriately selected pa-
tients with breast carcinoma who are treated with BCT or who
undergo mastectomy.7,8 In general, optimal candidates for BCT are
defined as patients who have a solitary primary breast lesion that can
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undergo excision and achieve negative microscopic
margins and who have no medical contraindications
to chest wall radiation; these factors have been re-
viewed extensively elsewhere.9,10 Among patients who
are treated with BCT, 9.3–22% will develop a locore-
gional recurrence at follow-up ranging from 40
months to 172 months despite careful patient selec-
tion.11 This form of disease recurrence can predict a
greater risk of distant metastatic disease. Data from
the National Surgical Adjuvant Breast and Bowel
Project (NSABP) B-06 trial revealed that women who
developed an in-breast tumor recurrence after they
received BCT were 3.41 times more likely to develop a
distant recurrence compared with patients who re-
ceived BCT who did not develop a local recurrence.12
In addition, it has been reported that younger women
with breast carcinoma have a greater risk of local
recurrence for BCT;13 and it is known that African-
American women have a younger age distribution for
breast carcinoma.1,4
Therefore, it is logical to ask whether African-
American patients with breast carcinoma have in-
creased locoregional recurrence rates after BCT. The
preponderance of available data suggests that, even if
African-American women with breast carcinoma ex-
perience different patterns of locoregional recurrence,
it is likely to be a manifestation of primary tumor
biology that cannot be altered by categorically deny-
ing them BCT. This is a crucial message. Clinicians
must remain cognizant of the fact that greater long-
term risk for disease-related mortality does not indi-
cate ineligibility for BCT.
In the most comprehensive study of possible eth-
nicity-related variation in BCT, Pierce et al.14 reported
outcome for 75 African-American women and 615
white women with Stage I or II breast carcinoma who
were treated at the Hospital of the University of Penn-
sylvania and the Fox Chase Cancer Center with exci-
sional biopsy, axillary lymph node dissection, and
breast irradiation. The African-American patients
were significantly younger compared with the white
patients (29% of African-American patients were age
 40 years compared with 18% of white patients; P
 0.02). At 5 years, local (in-breast only) recurrence
rates were similar for African-American patients and
white patients (5% vs. 6%). However, the African-
American patients had significantly higher rates of
regional recurrence as a component of first failure
(16% vs. 4%; P  0.001) and distant recurrence as the
only site of first failure (20% vs. 11%; P  0.01). Spe-
cifically, rates of regional failure in the supraclavicular
lymph nodes differed only by race, whereas the fre-
quency of axillary and internal mammary failure was
comparable between the groups. The subset of young
African-American patients had the worst outcome,
with a 5-year overall survival rate for African-American
patients age  40 years of 78% compared with 92% for
the subset of young white patients (P  0.01). Overall
survival rates for the older African-American patients
and white patients were similar (84% vs. 91%).
The Fox Chase Cancer Center recently reported
patterns of regional failure and the impact of regional
radiotherapy in 346 women (12% African American)
with early-stage, lymph node positive breast carci-
noma who received BCT at their institution.15 Re-
gional failure was defined as recurrence in the supra-
clavicular and/or axillary regions at any time; rates of
recurrence in each of the lymph node regions and
patterns of first failure were not defined specifically.
Overall, the 5-year cumulative incidence of regional
lymph node failure was 19% for African-American pa-
tients and 1% for white patients (P  0.0001). For the
subset of patients with one to three positive axillary
lymph nodes who were treated with breast irradiation
only (rather than breast and regional irradiation), the
regional recurrence rate for African-American patients
was 23% compared with a rate of 2% for white pa-
tients. The addition of regional irradiation decreased
the regional recurrence rates to 12% and 0%, respec-
tively (P  0.0001). Although these results are provoc-
ative, information is not available regarding either the
percent of women who failed only in the axilla or the
median number of axillary lymph nodes dissected in
each group. Because management options and prog-
noses differ for an isolated axillary recurrence, versus
a supraclavicular recurrence, versus regional failures
with concurrent systemic failures, no conclusions re-
garding regional irradiation based solely on ethnicity
can be made until additional data specifically outlin-
ing patterns of failure are provided. Further investiga-
tion of these patterns is warranted, however, in light of
the ongoing controversy regarding whether or not re-
gional radiation should be offered to patients with
metastases in one to three axillary lymph nodes.16
Newman et al.17 reported the University of Texas
M. D. Anderson Cancer Center experience in a review
of African-American patients with breast carcinoma
who underwent surgery between 1975 and 1994. Of
211 African-American patients with T1 or T2 tumors,
the BCT rate was only 19%. With a median follow-up
of 67.8 months, no significant differences were found
in local recurrence or survival rates between the Afri-
can-American BCT and mastectomy groups. However,
local recurrence was associated with decreased sur-
vival in both treatment groups.
Muss et al.18 found similarly low rates of BCT use
among African-American women and white women
who were evaluated in the National Cancer Institute
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Black/White Cancer Survival Study. This project eval-
uated a subset of 160 African-American women with
breast carcinoma and 145 age-matched white women
with breast carcinoma who had Stage II, lymph node
positive disease. The use of BCT for African-American
patients was only 14%, compared with 28% for white
patients (P  0.004).
The NSABP B-06 study,19 which randomized
women with early-stage breast carcinoma to receive
BCT versus mastectomy, found a poorer prognosis
among African-American participants (5-year survival
rates, 74% vs. 89%), although specific data on local
recurrence rates in different ethnic subsets were not
reported.
The NSABP B-13 and B-14 studies,20 however, did
report an unexplained low rate of BCT use among
African-American patients compared with white pa-
tients. For the estrogen receptor negative participants
in the NSABP B-13 study, 22.2% of African-American
patients underwent lumpectomy compared with
35.8% of white patients (P  0.01); whereas, among
patients who were estrogen receptor positive in the
NSABP B-14 study, 20.7% of African-American pa-
tients received BCT compared with 40.8% of white
patients (P  0.001). Outcome, which is discussed
further below, focused on measures of survival rather
than locoregional recurrence.
Underuse of BCT by African-American women
was found to be a function of relatively lower socio-
economic status in a study by Michalski and Nat-
tinger21 of 41,937 Medicare patients with breast cancer
patients. In that series of older patients (age 65–79
years), the use of BCT was uniformly low among 13.3%
of 2339 African-American patients and 15.1% of white
patients with similar socioeconomic status.
Higher rates of BCT were seen among African-
American patients who were treated at the Henry Ford
Hospital in Detroit. Velanovich et al.22 found similar
rates (over one-third of patients) of BCT among 416
African-American patients and 834 white patients who
were treated between 1990 and 1997. No data on re-
currence patterns were reported in the NSABP, Medi-
care, or Detroit studies (Table 1).
It is interesting to note that Connor et al.23 re-
cently reported on BCT outcome in African-American
patients with Stage I or II breast carcinoma who were
treated at the University of Kansas Medical Center
between 1982 and 1998. With a mean follow-up of 53.4
months for 71 African-American patients who re-
ceived BCT, there were 8 local recurrences (11%). By
TABLE 1






(months) FindingsAfrican American White
Conner et al., 200023 71 204 Stage I/II; all treated with
BCT
53 Trend for higher local recurrence rate in African-
American women (n.s.)
Nicolaou et al., 199915 41a 301a Stage IIA/IIB; lymph
node positive; all
treated with BCT
73 Higher regional recurrence rate among African-
American women (19% vs. 1%; P  0.0001)
Velanovich et al., 199922 416 834 Stages I–IV; treatment
variable
NA Similar rates of BCT among African-American
women and white women (over one-third in
both groups)
Newman et al., 199917 211 NA T1–T2 tumors; treatment
variable
68 BCT rate 19.9%; similar local recurrence rates and
survival rates for BCT and mastectomy (9.8% vs.
8.9%)
Michalski and Nattinger, 199721 2339 37,462 Local or regional disease;
all Medicare patients
NA BCT rate lower for African-American women
compared with white women (13.1% vs. 15.4%;
P  0.001); low BCT rates related to
socioeconomic factors
Muss et al., 199218 160 145 Stage II; lymph node
positive; treatment
variable
NA Lower BCT rates among African-American women
compared with white women (22% vs. 40%; P 
0.004)
Pierce et al., 199214 75 615 Stage I/II; all treated with
BCT
56 Similar local recurrence rates for African-American
women and white women (5% vs. 6%); higher
regional recurrence rates for African-American
women (16% vs. 4%; P  0.001)
BCT: breast conservation therapy; n.s.: not significant; NA: not applicable.
a Sample size approximate, based on the percentage distribution reported in the study.
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comparison, there were 11 local recurrences among
208 similarly treated white patients (5%) at a mean
follow-up of 64.8 months. These differences were not
significantly different; however, the trend led the au-
thors to speculate that an ethnicity-related variation in
tumor aggressiveness may be in effect. It should be
noted, however, that there also was a trend for higher
rates of margin positivity among the African-American
patients (19% vs. 12%) as well as a relatively higher
proportion of Stage II disease (58% vs. 47%). Although
neither of these differences met statistical signifi-
cance, they raise the concern that the combination of
more advanced stage disease and suboptimal primary
tumor resection may have an impact on the poorer
rate of local disease control.
Collectively, these studies suggest that additional
efforts are necessary to educate African-American
women with breast carcinoma about the option of
BCT. The data demonstrate comparable rates of suc-
cess with breast conservation among African-Ameri-
can women and white women, as discussed above,
despite the younger age distribution in the African-
American cancer population. Any ethnicity-related
variation in primary tumor biology that may exist ap-
pears to exert similar influences on outcome regard-
less of a breast-sparing approach compared with a
mastectomy approach. Decisions to alter regional ra-
diotherapy recommendations based on ethnicity
await carefully designed trials that address patterns of
failure, quality of life, and survival outcomes and that
provide multivariate analyses correcting for con-
founding factors.
Systemic Therapy
The next issue to be addressed concerns the possible
existence of ethnicity-related variation in response to
systemic therapy. Adjuvant chemotherapy and/or
hormonal therapy for both patients with lymph node
negative breast carcinoma and patients with lymph
node positive breast carcinoma is now accepted as a
means of reducing the odds of developing recurrent
breast carcinoma and death from disease by up to
30%.24,25 Are similar proportional gains in outcome
achieved in African-American patients and white pa-
tients with breast carcinoma? If there is a greater prev-
alence of biologically resistant tumors in the African-
American patient population, or if there is ethnicity-
related variation in drug metabolism, then this may
not be the case. The concept regarding differences in
drug metabolism has been cited by some investiga-
tors26,27 and is supported by known interethnic differ-
ences in several enzyme systems. This question should
be addressed at least in part by data from prospective,
randomized trials of adjuvant systemic therapy that
stratify the population of patients with breast carci-
noma and that standardize management as well as
follow-up. Subset analyses from some previously re-
ported multiinstitutional trials have been be reviewed,
because these are more likely to have sample sizes
adequate for meaningful comparisons.
The NSABP trials have generated substantial in-
formation regarding systemic therapy for patients
with breast carcinoma. Primary pathologic and dis-
ease response results for African-American partici-
pants have been reported and were reviewed recently
by Dignam.28 The NSABP B-09 study29 evaluated mel-
phalan and 5-fluorouracil (5FU) with or without ta-
moxifen for patients with Stage II breast carcinoma. A
persistent survival disadvantage was noted for the Af-
rican-American patients compared with the white pa-
tients (crude 5-year survival for the melphalan-5FU
arm: 52% vs. 68%; P  0.01; crude 5-year survival for
the melphalan-5FU-tamoxifen arm: 57% vs. 65%).
Controlling for the greater prevalence of adverse tu-
mor features (e.g., lower estrogen receptor positivity;
37% vs. 52%, respectively) eradicated a portion of this
survival disparity. The adjusted 5-year survival rate for
African-American patients was lower but was not sig-
nificantly different from the rate for white patients.
The NSABP B-13 and B-14 studies20 evaluated ad-
juvant therapy in patients with lymph node negative,
estrogen receptor negative, and estrogen receptor
positive (respectively) breast carcinoma. Subset anal-
yses of these trials, with 311 African-American patients
and 4625 white patients, revealed equivalent treat-
ment benefits for adjuvant systemic therapy across
ethnic categories. These data provided strong support
for the concept of equally aggressive adjuvant treat-
ment resulting in similar outcomes.
Roach et al.30 reported on ethnicity-related out-
come among participants in the Cancer and Leukemia
Group B (CALGB) 8541 trial, in which 1572 patients
with lymph node positive breast carcinoma (12% Af-
rican American) were randomized to one of three dif-
ferent dose schedules for a doxorubicin-based chemo-
therapy regimen. Although univariate analysis
revealed worse overall survival and decreased time to
recurrence for the African-American patients, multi-
variate analysis (adjusting for extent of axillary lymph
node involvement, estrogen receptor status, age, and
treatment arm) eliminated the ethnicity-related sur-
vival disparity.
Similarly, Briele et al.31 suggested that the survival
disadvantage seen among African-American patients
with breast carcinoma may be minimized with appro-
priately aggressive care. In a retrospective review of
526 African-American women with Stage I–III disease
who were treated at Cook County Hospital in Chicago,
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the authors found that 5-year and 10-year survival
rates were similar to the rates in historic controls. The
authors also found that adjuvant systemic therapy
resulted in substantial survival gains among patients
with lymph node positive disease. It is interesting to
note that the greatest benefit was seen among patients
with one to three positive lymph nodes.
Conflicting results were reported by Elledge et
al.32 in a study that evaluated primary tumor features
and survival among 4885 white patients, 1016 African-
American patients, and 777 Hispanic patients with
breast carcinoma. The African-American patients had
the lowest rates of estrogen receptor positive tumors,
and African-American patients with lymph node pos-
itive disease experienced significantly worse disease
free and overall survival. These results could not be
explained by differences in use of systemic adjuvant
therapy.
Data on primary breast tumor response after in-
duction chemotherapy in African-American women
would be meaningful; however, this area of research
has been particularly limited. African-American
women are more likely to be diagnosed with locally
advanced breast carcinoma (LABC), and standard-of-
care management for patients with LABC includes
neoadjuvant chemotherapy.33 This approach permits
tumor shrinkage that facilitates subsequent surgical
resection, and in vivo assessment of response to treat-
ment is predictive of outcome. Although survival from
LABC generally ranges from 30% to 70%, survival for
patients who achieve a complete clinical and patho-
logic response is substantially better. There will be a
greater likelihood of increasing the pool of these com-
plete responders as novel systemic therapy agents be-
come available as crossover regimens. The University
of Texas M. D. Anderson Cancer Center reviewed out-
come among 373 patients with LABC who participated
in prospective trials of induction chemotherapy;34 the
5-year survival rate for the complete responders was
88%. Subset analysis of this data set based on ethnicity
revealed similar disease free and overall survival rates
for African-American patients and white patients; a
trend was noted for the African-American patients age
 50 years to be more likely to have a clinical partial or
complete response, but this did not translate into a
survival advantage.35
Ethnicity-related variation in response to treat-
ment for metastatic carcinoma was evaluated by the
Piedmont Oncology Association.36 Their study of 74
African-American patients and 74 white patients with
advanced disease who were treated on the same sys-
temic therapy protocols demonstrated poorer survival
for the African-American patients despite apparent
equality of clinical management and treatment. The
studies regarding adjuvant, induction, and palliative
systemic therapy results in African-American patients
underscore the importance of pursuing innovative
and aggressive systemic therapy options in this pa-
tient population that is known for its high risk of
disease recurrence and mortality.
Delivery of Care and Other Issues
Appropriately aggressive local and systemic therapy
for African-American patients with breast carcinoma
appears to result in favorable outcome for the majority
of women. However, several studies have documented
a survival disadvantage for African-American patients
with breast carcinoma, even after controlling for stage
at diagnosis and equivalent access to medical
care.4,37–39 This constellation of findings prompts the
question: Are ethnicity-related disparities in breast
carcinoma outcome explained by disparities in treat-
ment offered and/or delivered to African-American
patients?
Looking at the BCT data, it appears that the low
rate of BCT may be related at least in part to poorly
informed patients. However, it also is possible that
there are socioeconomic and cultural barriers to com-
pleting the 6-week course of radiation therapy that is
a necessary component of this treatment alternative.
Breen et al.40 reevaluated data from the National
Cancer Institute Black/White Cancer Survival Study by
stratifying patients based on whether they received
minimum expected therapy, as defined by stage-re-
lated standard-of-care practices and National Institute
of Health Consensus Conferences. Overall, 21% of Af-
rican-American women, compared with 15% of white
women, did not receive this minimum expected care.
CONCLUSIONS
This review has focused on discrete ethnicity-related
variations in outcome after standard treatment for
patients with breast carcinoma. Several important re-
lated issues have not been reviewed but certainly de-
serve mention. Future areas of research should eval-
uate results from lymphatic mapping and sentinel
lymph node biopsy for African-American women with
breast carcinoma. This is worthy of particular atten-
tion, because African-American women are at greater
risk for presenting with lymph node positive disease
and because it will generate data regarding the inci-
dence of micrometastatic disease in this patient pop-
ulation. In addition, some studies41,42 have demon-
strated that African-American women are at greater
risk for complications and disability related to stan-
dard axillary lymph node dissection. The interaction
of ethnicity-related variations in body mass index and
250 CANCER Supplement January 1, 2003 / Volume 97 / Number 1
the incidence of comorbidities also deserves closer
attention in future studies.
From the available data, it can be concluded that
African-American women with breast carcinoma po-
tentially may respond as well to appropriate local and
systemic therapy as white women with breast carci-
noma. Health care providers should take special care
to insure that these women are fully informed of BCT
options. There are data indicating that African-Amer-
ican women are at high risk for disease-related mor-
tality, and early evidence suggests that they are at
greater risk for particular patterns of locoregional re-
currence. Explanations for these findings will be ob-
tained only by appropriate representation and possi-
bly by oversampling of African-American patients in
prospective, randomized treatment trials.
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